Samay founder and CEO Dr. Maria Artunduaga says things changed pretty quickly for her startup after winning the MedTech ...

A higher proportion of patients with pulmonary sarcoidosis were steroid-free after 48 weeks of treatment with efzofitimod vs.

One year after launch of real-world CLARIFY study, preliminary data from the first 1,000 enrolled patients will be ...

Dr Aaron Holley explores APRV vs low tidal volume ventilation in ARDS, weighing physiologic promise against the need for ...

Interstitial Lung Disease (ILD): In the PHAROS trial, 1 patient (1%) receiving MEKTOVI with BRAFTOVI developed pneumonitis. Assess new or progressive unexplained pulmonary symptoms or findings for ...

Roger Jeffs, Chief Executive Officer of Liquidia, said: ”Our first R&D Day represents an important milestone as we bring together our team with recognized experts in the fields of PAH and PH-ILD to ...

Highlights include clinical data from Phase 3 studies in Community Acquired Pneumonia (CABP) and microbiologic data from a Phase 2 study in ...